2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-carbonitrile | 868166-21-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-carbonitrile
• 英文别名: 5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-carbonitrile；5'-isopropyl-2'-methoxy-4-trifluoromethyl-biphenyl-2-carbonitrile；2-(2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)benzonitrile
• CAS: 868166-21-6
• 化学式: C₁₈H₁₆F₃NO
• 分子量: 319.326
• InChiKey: KFYDWIIILHRHEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-carbonitrile 在 lithium aluminium tetrahydride 、 N,N-二异丙基乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 6.33h， 生成 methyl {[5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl}carbamate
  参考文献：
  名称：

  Discovery of Substituted Biphenyl Oxazolidinone Inhibitors of Cholesteryl Ester Transfer Protein

  摘要：

  Recently, there has been a strong interest in the ability to increase levels of high density lipoprotein-cholesterol (HDL-C). This interest stems from the hypothesis that such an elevation in HDL-C will decrease the likelihood of cardiovascular disease. Inhibition of cholesteryl ester transfer protein (CETP) has been shown to elevate HDL-C levels in human subjects. This letter describes the discovery of a novel and potent (<100 nM IC(50) for the inhibition of CE transfer) CETP inhibitor scaffold containing an oxazolidinone core.

  DOI：

  10.1021/ml100309n
• 作为产物：
  描述：

  4-氨基-3-碘三氟甲苯 在 四(三苯基膦)钯 、 亚硝酸特丁酯 、 二碘甲烷 、 sodium carbonate 作用下， 以 2-甲基-1,2-丙二醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.84h， 生成 2'-methoxy-5'-(propan-2-yl)-4-(trifluoromethyl)biphenyl-2-carbonitrile
  参考文献：
  名称：

  Discovery of Substituted Biphenyl Oxazolidinone Inhibitors of Cholesteryl Ester Transfer Protein

  摘要：

  Recently, there has been a strong interest in the ability to increase levels of high density lipoprotein-cholesterol (HDL-C). This interest stems from the hypothesis that such an elevation in HDL-C will decrease the likelihood of cardiovascular disease. Inhibition of cholesteryl ester transfer protein (CETP) has been shown to elevate HDL-C levels in human subjects. This letter describes the discovery of a novel and potent (<100 nM IC(50) for the inhibition of CE transfer) CETP inhibitor scaffold containing an oxazolidinone core.

  DOI：

  10.1021/ml100309n

文献信息

• [EN] CETP INHIBITORS<br/>[FR] INHIBITEURS DE CETP
  申请人：MERCK & CO INC

  公开号：WO2005100298A1

  公开（公告）日：2005-10-27

  Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

  公式（I）的化合物，包括这些化合物的药用可接受盐，是CETP抑制剂，可用于提高HDL-胆固醇，降低LDL-胆固醇，并用于治疗或预防动脉粥样硬化。在公式1的化合物中，A1和A2分别是芳香环，5-6成员杂环，芳香环与杂环融合，苯环与杂环融合或环烷基环。
• [EN] CETP INHIBITORS<br/>[FR] INHIBITEURS DE LA CETP
  申请人：MERCK & CO INC

  公开号：WO2006014357A1

  公开（公告）日：2006-02-09

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalky substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalky substituent connected directly to the ring or attached to the ring through a -CH2-.

  具有公式I结构的化合物，包括这些化合物的药用盐，是CETP抑制剂，可用于提高HDL-胆固醇，降低LDL-胆固醇，并用于治疗或预防动脉粥样硬化：在公式I的化合物中，B或R2是具有邻位芳基、杂环、苯并杂环或苯环烷基取代基的苯基，而5-成员环的另一个位置具有直接连接到环或通过-CH2-连接到环的芳基、杂环、环烷基、苯并杂环或苯环烷基取代基。
• CETP inhibitors
  申请人：Ali Amjad

  公开号：US20060040999A1

  公开（公告）日：2006-02-23

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R 2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH 2 —.

  具有I式结构的化合物，包括该化合物的药学可接受的盐，是CETP抑制剂，可用于提高高密度脂蛋白胆固醇，降低低密度脂蛋白胆固醇，以及治疗或预防动脉粥样硬化：在I式化合物中，B或R2是具有正交芳基，杂环，苯并杂环或苯并环烷基取代基的苯基取代基，并且5元环上的另一个位置具有芳香，杂环，环烷基，苯并杂环或苯并环烷基取代基，直接连接到环或通过—CH2—连接到环。
• DIBENZYL AMINE COMPOUNDS AND DERIVATIVES
  申请人：Chang George

  公开号：US20090239865A1

  公开（公告）日：2009-09-24

  Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  二苯甲胺化合物和衍生物，含有这些化合物的药物组合物以及使用这些化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和三酰甘油，并因此治疗由低水平的高密度脂蛋白胆固醇和/或高水平的低密度脂蛋白胆固醇和三酰甘油恶化的疾病，例如动脉粥样硬化和心血管疾病等哺乳动物，包括人类。
• Cetp Inhibitors
  申请人：Ali Amjad

  公开号：US20070225365A1

  公开（公告）日：2007-09-27

  Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A 1 and A 2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

  公式I的化合物，包括化合物的药物可接受盐，是CETP抑制剂，可用于提高HDL-胆固醇，降低LDL-胆固醇，并用于治疗或预防动脉硬化。在公式1的化合物中，A1和A2分别是芳香环，5-6成员杂环环，芳香环与杂环环融合，苯环与杂环环融合或环状烷基。